Bupropion, smoking cessation, and health-related quality of life following an acute myocardial infarction. J Popul Ther Clin Pharmacol 2014;21(3):e346-56
Date
10/20/2014Pubmed ID
25326910Scopus ID
2-s2.0-84908137927 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
BACKGROUND: The use of bupropion, a smoking cessation aid, has been associated with improved health-related quality of life (HRQOL) in the general population of smokers; but, its effect on HRQOL in post-myocardial infarction (MI) patients remains unknown.
OBJECTIVES: To examine the effect of bupropion on HRQOL in post-MI patients who are attempting to quit smoking.
METHODS: To accomplish this objective, we used data from a randomized, double-blind, placebo-controlled trial in 392 hospitalized post-MI patients. Treatment duration was 9 weeks, and follow-up was 12 months. HRQOL was assessed via the EuroQol-5D (EQ-5D) questionnaire, which includes 5 dimensions (mobility, self-care, daily activities, pain/discomfort, and anxiety/depression). Analyses were restricted to patients (n=225) who completed the EQ-5D at baseline, 6 months, and 12 months.
RESULTS: Patients randomized to bupropion (n=109) and those randomized to placebo (n=116) experienced similar improvements in HRQOL during follow-up (difference in change in EQ-5D index from baseline to 6 months = 0.02, 95% confidence interval [CI] = -0.04, 0.08; from baseline to 12 months = 0.02, 95% CI = -0.04, 0.08). No between-group differences were observed in any of the 5 dimensions. Similar improvements in HRQOL were observed between patients who remained abstinent and those who relapsed. Lower baseline HRQOL, defined as having a HRQOL that was less than the median value, was associated with decreased smoking abstinence at 12 months follow-up (odds ratio OR =0.39, 95% CI = 0.22, 0.68).
CONCLUSIONS: Bupropion does not improve HRQOL among patients attempting to quit smoking post-MI.
Author List
Zhang DD, Eisenberg MJ, Grandi SM, Joseph L, O'Loughlin J, Paradis G, Lozano P, Filion KBAuthor
Pedro Lozano MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultBupropion
Double-Blind Method
Female
Humans
Logistic Models
Male
Middle Aged
Myocardial Infarction
Odds Ratio
Prevalence
Quality of Life
Quebec
Risk Factors
Risk Reduction Behavior
Smoking
Smoking Cessation
Smoking Prevention
Surveys and Questionnaires
Time Factors
Treatment Outcome
